Parvus Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
800 Dubuque Ave, South San Francisco, Ca...Phone Number
(415) 805-8251Website
www.parvustx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Parvus Therapeutics
Parvus Therapeutics Inc. is a clinical-stage company focused on developing proprietary pMHC nanomedicine drug candidates aimed at treating autoimmune diseases. Their innovative approach involves generating antigen-specific regulatory T cells (Tregs) to restore immune tolerance without compromising normal immune function. The company targets patients suffering from autoimmune diseases, offering a novel alternative to traditional treatments that broadly suppress the immune system. Parvus's research is based on the work of Dr. Pere Santamaria at the University of Calgary.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Parvus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Parvus Therapeutics launches new products
Funding: Get notified immidiatlly once Parvus Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if Parvus Therapeutics is spiking on competitors!
Parvus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Parvus Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Parvus Therapeutics recently announced quarterly report
Check if Parvus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Parvus Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Parvus Therapeutics
Compare insights from companies similar to Parvus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Parvus Therapeutics
<$5M
11-50
Private
-
2014
N/A
Company Profile Activity
Activity Insights
Parvus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Parvus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Parvus Therapeutics.
Parvus Therapeutics Tech Stack
A closer look at the technologies used by Parvus Therapeutics
Parvus Therapeutics News & Media
Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology
The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an exclusive worldwide license collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) for the development and [PR.com]Parvus Therapeutics Announces a Publication Describing the Cellular Origin of Treg Cells Generated Endogenously by Navacim Therapy
Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. [PR.com]Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201
Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function, today announced an agreement with National Resilience, Inc. (Resilience), for the tech transfer, scale-up and GMP manufacturing [PR.com]Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles
Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. [PR.com]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Parvus Therapeutics
Sign Up For FreeTo access detailed company insights
Parvus Therapeutics Inc. is a clinical-stage company focused on developing proprietary pMHC nanomedicine drug candidates aimed at treating autoimmune diseases. Their innovative approach involves generating antigen-specific regulatory T cells (Tregs) to restore immune tolerance without compromising normal immune function. The company targets patient... Read More
